Rivastigmine Transdermal System

DRUG2 trials

Sponsors

University of Bristol, Yale University

Conditions

Hallucinations, AuditoryParkinson DiseasePsychosis

Early Phase 1

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

RecruitingNCT04366518

Yale UniversityHallucinations, Auditory, Psychosis

Start: 2021-07-15End: 2032-08-31Target: 35Updated: 2025-06-05

Phase 3

CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

CompletedNCT04226248

University of BristolParkinson Disease

Start: 2020-01-02End: 2025-07-24Updated: 2025-09-29

Related Papers

Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.

2021-10-2916 citations